Search 

Syneos Health is the only company in the biopharmaceutical Looking for services industry purpose-built to create greater success for our customers. At Syneos Health, clinical and commercial live under the same roof and constantly share real world knowledge and insights that lead to getting the job done better, smarter and faster.

Syneos Health has around 24,000 + employees globally. We are headquartered in US, North Carolina and has more offices in more than 60 countries worldwide. In China, we have offices in Shanghai, Beijing and Dalian.

We call this new way of collaborative working the Biopharmaceutical Acceleration Model or BAM.

TheraIndx Life Sciences is a preclinical Contract Research Services Company based in Bangalore, India with Management team who have worked in Global Pharma in Drug Discovery and development progressing molecules from discovery to clinic. TheraIndx offers modular and integrated drug Discovery and development services to Pharma, Biotech and academic institutions across the globe. TheraIndx offers a wide range of animal disease models in infection, oncology, CNS and metabolic disorders along with Biomarker assays. Our Business models are Fee for services and also in partnerships till IND filing.

Multi cancer early detection screening diagnostic solutions (liquid biopsy)

Tianda Pharmaceutical Limited (455.HK) is a Hong Kong listing company, concentrated in the R&D, manufacturing and distribution of biochemicals, biologics, biosimilars, CHC, dietary supplements and TCM.The company has two pharmaceutical factories, one TCM herbal slice plant, one GSP Company, one CSO company and a R&D center, and several operating
platforms separately located in Sydney, Hong Kong, Shenzhen, Zhuhai and Kunming.Shanghai Pharmaceutical Holding Co Limited, one of the top three largest pharmaceutical companies in China, has invested in Tianda Pharmaceuticals.
The mutual parties share their resources, therefore Tianda could explore and develop its business by utilizing the resources of Shanghai Pharmaceuticals.

TissUse is a Berlin, Germany-based, vibrant growth company who has developed a unique "Multi-Organ-Chip" platform that provides unprecdented preclinical insight on the systemic level using human tissue. This enabling technology platform consists of a miniaturized construct that closely simulates the activity of multiple human organs in their true physiological context. TissUse's Multi-Organ-Chips provide a completely new approach to predict, for example, toxicity, ADME profiles and efficacy in vitro, reducing and replacing laboratory animal testing and streamlining human clinical trials.
TissUse is additionally applying its platform and know-how to develop spin-off programs in a variety of tissue and organ repair areas starting with the cosmetic market of hair transplants.

Tonghua Dongbao Pharmaceutical Co.,LTD is a healthy medicine enterprise which devotes to R&D, manufacturing and sales of high quality pharmaceutics. The company was established in 1985, listed in Shanghai Stocks Exchange in 1994 (600867).By the end of 2019, we have 2,700 employees including 300 R& D persons. Tonghua Dongbao has became a well known industrial manufacturer of recombinant human insulin, and has constructed National enterprise technical center and Post-doctoral Scientific research station.

It is a University

WEGO HOLDING COMPANY LIMITED (“WEGO”) was established in March 1988, and it principal business focus on medical devices and pharmaceuticals. In addition, WEGO develops some other business such as real estate and investment. WEGO has 8 industry groups and more than 30 subsidiaries. WEGO Holding's subsidiary ---SHANDONG WEIGAO GROUP MEDICAL POLYMER CO., LIMITED is listed in Hong Kong.

The main products of WEGO are infusion sets, syringes, blood transfusion equipments, heart stents, intracardiac consumables，IV catheters and special needles, blood purification equipments and consumables, orthopedic materials, operating room equipments and accessories, wound care products, minimally invasive instruments and equipments, ICU products and accessories, high-capacity injections and pharmaceuticals, renal products, biological diagnostic reagents, PVC & non-PVC materials and so on. WEGO now has products in more than 30 series, 400 categories and 60,000 specifications products, and has become one of the most reliable suppliers of medical system solutions in the world. At the same time, WEGO actively takes part in healthcare service and provides renal dialysis service.

In addition, under the branding strategy, the WEGO products are sold in more than 30 provinces and municipalities, which covered 81.3% of tertiary hospitals and 77.2% of blood banks in China, and also exported to over 70 countries and areas. WEGO is trying to become an international company, trying to achieve the vision of “To be one of the global elites; Pioneer in Asia; Most respectable medical device and medication enterprise”, and trying to make contributions to China's medical and healthcare industry.

The WuXi AppTec Research Services Division (RSD) supports its clients in the discovery and development of future therapeutics. Through comprehensive discovery and technology platforms, peer-recognised scientific leadership and expertise in oncology, immunology, infectious disease, neurosciences, fibrosis, cardiovascular and metabolic disease, RSD works collaboratively to rapidly advance programs from target through to preclinical selection and beyond.

RSD’s discovery platform encompasses biology, chemistry, structural biology and biophysics, in addition to the capabilities of newly acquired HD Biosciences (HDB), and is trusted by over 1,900 international clients, ranging from pharma and biotech to academia and non-profit institutions.

Xuanzhu Biopharmaceutical was founded in 2002. In 2012, it became a wholly-owned subsidiary of Sihuan Pharmaceutical. In 2018, Xuanzhu Biopharmaceutical spun-off and became independent, with a registered capital of RMB1.15 billion. Different from other emerging unprofitable biotechnology companies, Xuanzhu Biopharmaceutical is one of the few domestic innovative drug companies with a complete research and development industry chain. It has not only more than a dozen innovative R&D products, but also support from a leading domestic pharmaceutical company in Sihuan Pharmaceutical. With strong production and commercialization capabilities, Xuanzhu Biopharmaceutical possesses the potential of becoming an international enterprise integrating R&D, manufactuing and marketing platforms.